Advancing EU Health Technology Assessment: Insights from the HAG Meeting

By João L. Carapinha

January 20, 2025

In this article we report on a virtual meeting of the Heads of HTA Agencies Group (HAG) held on January 14, 2025, two days after the implementation of the EU Health Technology Assessment (HTA) Regulation. The meeting discussed key developments, including the drafting of implementing acts for joint scientific consultations and clinical assessments. Also, they focused on the operationalization of the 2025 Work Programme for the new joint EU-level HTA framework. The HAG also addressed various initiatives, such as the HAG INSIGHT initiative and the launch of the HAG Digital Medical Device Working Group.

Key Insights

The HAG meeting concentrated on the implementation of the EU Health Technology Assessment Regulation, particularly the drafting and approval of procedural rules for joint scientific consultations (JSC) and joint clinical assessments (JCA) of medical devices and IVD medical devices.

The group discussed ongoing initiatives, including the HAG INSIGHT initiative aimed at enhancing the capacity and expertise of EU HTA bodies. They also discussed the launch of the HAG Digital Medical Device Working Group.
– Positive feedback from stakeholder events organized in 2023 and 2024 was highlighted, alongside discussions about the development of the HAG Strategic Plan 2025-2028.
– Data transparency in EU joint clinical assessments and the evaluation of the EU Health Technology Assessment Regulation under Article 31 were also key topics.

Context

The EU Health Technology Assessment Regulation (EU) 2021/2282 came into effect on January 12, 2025. Its goal is to reduce duplication for national HTA authorities and the industry while improving the evidence base for HTA assessments. The regulation encompasses joint clinical assessments and scientific consultations, which are essential for harmonizing HTA processes across EU member states. The preparatory phase of this regulation lasted from January 2022 to January 2025, involving the development of implementing legislation, guidance documents, and stakeholder engagement.

Implications

The implementation of the EU Health Technology Assessment Regulation is expected to streamline and standardize the HTA process, potentially leading to more efficient and cost-effective assessments of health technologies. This reform may significantly impact patient access by lessening the financial burden linked to duplicate assessments and by enhancing the quality of evidence for decision-making. Enhanced data transparency in joint clinical assessments, as discussed by the HAG, will likely boost the reliability and comparability of HTA outcomes, benefiting both healthcare providers and patients. The HAG INSIGHT initiative and other capacity-building efforts will ensure that EU HTA bodies possess the expertise necessary to implement the HTA Regulation effectively while maintaining high standards in health technology evaluations.

The regulation emphasizes voluntary cooperation among member states and stakeholder engagement, which includes patient and clinician organizations, industry representatives, and national authorities. This collaboration can drive better health outcomes and more informed policy decisions. The inclusion of new members in the HAG and the expansion of its working groups, such as the HAG Digital Medical Device Working Group, will further increase the group’s representativeness and efficacy in supporting the implementation of the HTA Regulation across the EU.

Reference url

Recent Posts

prior authorization elimination
   

Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?

🚀 Are prior authorizations holding back patient access to crucial medications?

Optum Rx is set to eliminate prior authorizations for about 80 drugs starting May 1, 2025, streamlining access to treatments for chronic conditions like cystic fibrosis and asthma. This significant move is aimed at reducing unnecessary administrative burdens, ultimately enhancing patient care.

Curious about the implications for the healthcare system and potential cost savings? Dive into the full article for an in-depth look!

#SyenzaNews #healthcare #HealthEconomics

South Africa cannabis regulations
     

South Africa Cannabis Regulations: Government Withdraws Ban for New Framework Development

🌿 Curious about the future of cannabis in South Africa?

Recent developments have seen the government retract its ban on hemp and cannabis food products, signaling a major shift towards a more responsible regulatory framework. With a focus on stakeholder consultation, this move aims to foster industry growth while prioritizing public health.

Explore how these changes are set to reshape the landscape of the cannabis industry in South Africa and beyond!

#SyenzaNews #HealthEconomics #MarketAccess

lumped parameter model
      

Advancing Heart Transplantation: The Role of the Lumped Parameter Model

🫀 How can a new model improve heart transplantation?

A recent study introduces a **lumped parameter model (LPM)** designed to enhance the evaluation of donor heart function during ex vivo perfusion, aiming to boost donor heart utilization and reduce primary graft dysfunction rates. This innovative approach holds promise for improving clinical decision-making and outcomes in heart transplantation.

Dive into the article for insightful details on how LPMs could reshape the future of cardiac care!

#SyenzaNews #HealthcareInnovation #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.